Several new ovarian cancer drugs have received priority review from the FDA following promising clinical trial results, and the developments mark a genuine turning point for patients who have had limited options for years. Most notably, pembrolizumab combined with paclitaxel earned FDA approval on February 10, 2026, after the KEYNOTE-B96 trial demonstrated that women with platinum-resistant ovarian cancer lived a median of 18.2 months compared to 14.0 months on placebo. That may not sound dramatic on paper, but it represents the first time an immune checkpoint inhibitor regimen has shown a significant overall survival benefit in a Phase III ovarian cancer trial.
For anyone caring for a loved one with both cognitive decline and a cancer diagnosis, understanding these treatment advances matters because the intersection of cancer care and dementia caregiving creates unique challenges around decision-making, treatment tolerance, and quality of life. Beyond pembrolizumab, two other drugs have also moved through the FDA pipeline at accelerated speed. Avutometinib combined with defactinib received accelerated approval in May 2025 for a rare subtype called KRAS-mutant low-grade serous ovarian cancer, while relacorilant paired with nab-paclitaxel has an NDA accepted with a target decision date of July 11, 2026. This article covers what each of these drugs does, how the trial results compare, what the approval timelines look like, and what families navigating both cancer care and cognitive health concerns should know about managing these complex treatment decisions.
Table of Contents
- What Does Priority Review Mean for New Ovarian Cancer Drugs and Their Trial Results?
- How Pembrolizumab Changed the Immunotherapy Landscape for Ovarian Cancer
- A Rare Subtype Gets Its First Targeted Therapy
- Comparing Survival Gains Across the Three New Treatments
- The Relacorilant Story and What Its Pending Decision Means
- Managing Cancer Treatment Decisions When Dementia Is Part of the Picture
- What the Next Year Looks Like for Ovarian Cancer Treatment
- Conclusion
- Frequently Asked Questions
What Does Priority Review Mean for New Ovarian Cancer Drugs and Their Trial Results?
Priority review is an FDA designation that shortens the agency’s review timeline from the standard ten months to roughly six months. It does not guarantee approval, but it signals that the FDA considers a drug to address a serious condition with an unmet medical need. In the case of pembrolizumab for ovarian cancer, the FDA granted priority review on October 18, 2025, for the supplemental biologics license application submitted by Merck. Less than four months later, the drug was approved. For context, many cancer drugs spend years in regulatory limbo, so this pace reflects genuine urgency driven by strong clinical evidence. The trial behind the pembrolizumab approval, KEYNOTE-B96, enrolled 643 patients in a multicenter, randomized, double-blind, placebo-controlled study.
Among the 466 patients whose tumors expressed PD-L1 at a combined positive score of 1 or higher, the combination of pembrolizumab with paclitaxel (with or without bevacizumab) achieved a median progression-free survival of 8.3 months compared to 7.2 months with placebo. The overall survival benefit was more striking: 18.2 months versus 14.0 months, with a hazard ratio of 0.76. These numbers matter because platinum-resistant ovarian cancer has historically been one of the most difficult cancers to treat, and immunotherapy had repeatedly failed to move the needle in ovarian cancer before this trial. It is worth noting that priority review was also granted for avutometinib and defactinib before their accelerated approval in may 2025. In that case, the designation reflected the fact that KRAS-mutant low-grade serous ovarian cancer had no specifically approved drug combination at all. The FDA recognized that even a Phase II trial with 57 patients warranted faster action when there is literally nothing else approved for that population.
How Pembrolizumab Changed the Immunotherapy Landscape for Ovarian Cancer
For years, oncologists watched immunotherapy transform outcomes in melanoma, lung cancer, and bladder cancer while ovarian cancer remained stubbornly resistant to checkpoint inhibitors. Multiple trials had failed. The assumption in much of the oncology community was that ovarian cancer’s tumor microenvironment simply did not respond to immune-based approaches the way other cancers did. KEYNOTE-B96 upended that assumption, though with an important caveat: the benefit was limited to patients whose tumors express PD-L1 at a combined positive score of 1 or higher. Patients with PD-L1-negative tumors did not see the same benefit, which means biomarker testing is essential before pursuing this treatment. However, if a patient has cognitive impairment or dementia alongside an ovarian cancer diagnosis, the decision to pursue pembrolizumab-based therapy becomes considerably more complex.
Immunotherapy can cause immune-related adverse events including colitis, pneumonitis, hepatitis, and neurological side effects that may be harder to identify and report in someone who already has communication difficulties. A caregiver who is managing a loved one with both conditions needs to be especially vigilant about changes in behavior, appetite, or energy levels that could signal treatment complications rather than dementia progression. The treatment showed meaningful survival gains, but those gains need to be weighed against the patient’s overall cognitive status and ability to tolerate and report side effects. The approval also applies specifically to patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one to two prior therapies. This is not a first-line treatment and is not indicated for patients who are still responsive to platinum-based chemotherapy. Families should understand this distinction clearly, because pushing for an immunotherapy approach when the cancer is still platinum-sensitive could mean missing out on more effective standard treatments.
A Rare Subtype Gets Its First Targeted Therapy
Low-grade serous ovarian cancer accounts for a small fraction of all ovarian cancer cases, but for the women who have it, treatment options have been painfully limited. Unlike its high-grade counterpart, low-grade serous ovarian cancer tends to grow more slowly but responds poorly to conventional chemotherapy. The accelerated approval of avutometinib combined with defactinib in May 2025 gave this population its first-ever approved drug combination specifically designed for their disease, targeting the KRAS mutation that drives many of these tumors. The RAMP-201 trial, a Phase II open-label study, enrolled 57 patients with recurrent KRAS-mutated low-grade serous ovarian cancer who had received at least one prior systemic therapy. The overall response rate was 44 percent, and responses lasted between 3.3 and 31.1 months. Median progression-free survival for KRAS-mutant patients reached 22 months.
To put that in perspective, prior treatment options for these patients typically offered response rates in the single digits or low teens. A 44 percent response rate in this context is not incremental improvement; it is a fundamentally different outcome. The side effect profile, however, deserves honest discussion. Nausea occurred in 67 percent of patients, diarrhea in 58.3 percent, and elevated creatine phosphokinase in 60 percent. Ten percent of patients discontinued treatment entirely due to adverse events. For a patient who is also managing early-stage cognitive decline, persistent nausea and diarrhea can contribute to dehydration, confusion, and worsening cognitive function. Caregivers should work closely with the oncology team to establish anti-nausea protocols and hydration plans before treatment begins, not after symptoms become unmanageable.
Comparing Survival Gains Across the Three New Treatments
When families are presented with treatment options, one of the most natural questions is which drug offers the best chance at longer survival. Direct comparisons across different trials are unreliable because each study enrolled different patient populations, but the headline numbers provide useful context. Pembrolizumab combined with paclitaxel showed a median overall survival of 18.2 months versus 14.0 months for placebo in PD-L1-positive platinum-resistant disease. Relacorilant combined with nab-paclitaxel showed a median overall survival of 15.97 months versus 11.50 months for nab-paclitaxel alone in the ROSELLA trial, with updated data showing a 35 percent reduction in the risk of death (hazard ratio 0.65, p=0.0004). Avutometinib and defactinib, meanwhile, showed a median progression-free survival of 22 months, but this was in a different population entirely: KRAS-mutant low-grade serous disease, which behaves very differently from platinum-resistant high-grade disease. The tradeoff between these treatments often comes down to tumor biology and prior treatment history. Pembrolizumab requires PD-L1 expression and works through immune activation. Relacorilant is a cortisol modulator that enhances the effectiveness of chemotherapy by blocking the stress response that tumors exploit to resist treatment.
Avutometinib and defactinib target specific molecular pathways in KRAS-driven cancers. These are not interchangeable options. A patient’s specific cancer subtype, mutation status, and treatment history determine which, if any, of these drugs is appropriate. For families juggling cancer treatment with dementia caregiving, the practical differences between these regimens also matter. Pembrolizumab is given intravenously every three or six weeks, requiring clinic visits. Avutometinib and defactinib are oral medications taken at home, which may be simpler logistically but introduces adherence concerns for patients with memory impairment. Relacorilant is taken orally around infusion days, combining both modalities. Each approach creates different demands on caregivers.
The Relacorilant Story and What Its Pending Decision Means
Relacorilant, developed by Corcept Therapeutics, takes a completely different approach to treating platinum-resistant ovarian cancer. Rather than attacking the cancer directly or boosting the immune system, it blocks the glucocorticoid receptor, which means it interferes with the cortisol signaling that tumors use to survive chemotherapy. The ROSELLA trial enrolled 381 patients between January 2023 and April 2024, randomizing them to receive either relacorilant 150 mg orally on the day before, day of, and day after nab-paclitaxel infusion, or nab-paclitaxel alone at a slightly higher dose. Median progression-free survival was 6.54 months versus 5.52 months (hazard ratio 0.70, p=0.0076). The FDA accepted the new drug application and set a PDUFA target date of July 11, 2026. Until that decision, relacorilant is not commercially available.
Families should be cautious about media reports that frame this drug as already approved or available. It is not. The NDA acceptance means the FDA is reviewing the application, not that it has reached a decision. If approved, it would offer another option for women whose cancer has progressed through platinum-based chemotherapy, but the timeline between NDA acceptance and potential prescribing access typically extends several months beyond the PDUFA date as manufacturing, distribution, and insurance coverage logistics are finalized. One limitation worth flagging: the ROSELLA trial was open-label, meaning both patients and physicians knew which treatment arm they were assigned to. While this is common in oncology trials where blinding is difficult, it introduces potential bias in reporting of subjective outcomes. The overall survival data, however, is an objective endpoint and showed a robust 35 percent reduction in the risk of death, which is difficult to attribute to placebo effect.
Managing Cancer Treatment Decisions When Dementia Is Part of the Picture
When a patient with dementia faces an ovarian cancer diagnosis, the standard informed consent process breaks down in ways that clinical trial data cannot address. A woman with moderate Alzheimer’s disease may not be able to weigh the risks and benefits of adding immunotherapy to her chemotherapy regimen. Legal healthcare proxies, advance directives, and family discussions become the mechanism through which treatment decisions are made, and those conversations are among the most difficult in all of medicine.
Oncologists experienced in geriatric care recommend comprehensive geriatric assessments before initiating any new cancer treatment in patients with cognitive impairment. These assessments evaluate functional status, nutritional health, comorbidities, medication burden, and cognitive capacity. A patient who scores poorly on these measures may be better served by symptom management and palliative care than by aggressive treatment, even when the treatment has shown survival benefits in clinical trials. The KEYNOTE-B96, RAMP-201, and ROSELLA trials did not specifically enroll or analyze outcomes in patients with dementia, so applying their results to this population requires careful clinical judgment rather than direct extrapolation.
What the Next Year Looks Like for Ovarian Cancer Treatment
The period between now and the end of 2026 may bring the most significant expansion of ovarian cancer treatment options in over a decade. If relacorilant receives FDA approval by its July 2026 PDUFA date, three new mechanistically distinct treatment approaches will have entered the market within roughly fourteen months. Beyond these three, ongoing trials are exploring antibody-drug conjugates, novel immunotherapy combinations, and PARP inhibitor resistance strategies that could further expand the treatment landscape.
For the dementia caregiving community, these advances present both hope and complexity. More options mean more decisions, more clinic visits, more side effects to monitor, and more opportunities for treatment to extend meaningful time with family. The research is moving fast, and staying informed through trusted sources like the FDA drug approval announcements, the Ovarian Cancer Research Alliance, and your loved one’s oncology team remains the best strategy for navigating what comes next.
Conclusion
The approval of pembrolizumab with paclitaxel in February 2026, the accelerated approval of avutometinib and defactinib in May 2025, and the pending NDA review for relacorilant collectively represent a meaningful shift in how platinum-resistant and rare-subtype ovarian cancers can be treated. Each drug addresses a different mechanism and patient population, and none of them is a universal solution. The survival improvements are real and statistically significant, but they range from roughly four months of added median overall survival to disease stabilization measured in progression-free months.
For families managing the intersection of ovarian cancer and dementia, these developments require conversations that go beyond what the clinical trial data shows. Treatment decisions should be guided by the patient’s overall health status, cognitive capacity, quality of life goals, and the practical realities of caregiving. Talk with your oncologist about biomarker testing, treatment eligibility, and what realistic expectations look like for your specific situation. These new drugs open doors, but walking through them wisely requires the kind of careful, individualized decision-making that no headline can capture.
Frequently Asked Questions
Is pembrolizumab approved for all types of ovarian cancer?
No. The February 2026 FDA approval covers pembrolizumab combined with paclitaxel (with or without bevacizumab) specifically for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in patients whose tumors express PD-L1 at a combined positive score of 1 or higher and who have received one to two prior therapies.
What is the difference between priority review and accelerated approval?
Priority review shortens the FDA’s review period from about ten months to six months but does not change the evidence standard required for approval. Accelerated approval allows a drug to be approved based on a surrogate endpoint, such as tumor response rate, rather than overall survival, and typically requires confirmatory trials after approval.
Can someone with dementia participate in ovarian cancer clinical trials?
Most clinical trials require participants to provide informed consent, which can be a barrier for patients with significant cognitive impairment. Some trials allow legally authorized representatives to consent on a patient’s behalf, but this varies by study protocol and institutional review board requirements. Ask the treating oncologist about specific eligibility criteria.
Is relacorilant available to patients right now?
No. The FDA accepted the new drug application and set a PDUFA target date of July 11, 2026. Until the FDA makes an approval decision and the drug is commercially launched, relacorilant is not available outside of clinical trials or expanded access programs.
How do these new ovarian cancer treatments affect patients who also have cognitive decline?
The clinical trials for these drugs did not specifically study patients with dementia or cognitive impairment. Side effects such as nausea, diarrhea, fatigue, and immune-related adverse events may be harder to identify in patients who have difficulty communicating symptoms. A comprehensive geriatric assessment before starting treatment is recommended.
What is KRAS-mutant low-grade serous ovarian cancer?
It is a rare subtype of ovarian cancer that grows more slowly than high-grade serous disease but responds poorly to standard chemotherapy. KRAS mutations drive the growth of many of these tumors. The avutometinib and defactinib combination approved in May 2025 is the first therapy specifically approved for this subtype.
